Immunomodulatory Effect of Locoregional Therapy in the Tumor Microenvironment

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2023 Jan 25

PMID 36694462

Authors

Lin Xie

Zhiqiang Meng

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy appears to be a promising treatment option; however, only a subset of patients with cancer responds favorably to treatment. Locoregional therapy initiates a local antitumor immune response by disrupting immunosuppressive components, releasing immunostimulatory damage-associated molecular patterns, recruiting immune effectors, and remodeling the tumor microenvironment. Many studies have shown that locoregional therapy can produce specific antitumor immunity alone; nevertheless, the effect is relatively weak and transient. Furthermore, increasing research efforts have explored the potential synergy between locoregional therapy and immunotherapy to enhance the long-term systemic antitumor immune effect and improve survival. Therefore, further research is needed into the immunomodulatory effects of locoregional therapy and immunotherapy to augment antitumor effects. This review article summarizes the key components of the tumor microenvironment, discusses the immunomodulatory role of locoregional therapy in the tumor microenvironment, and emphasizes the therapeutic potential of locoregional therapy in combination with immune checkpoint inhibitors.

Citing Articles

High-intensity focused ultrasound ablation to increase tumor-specific lymphocytes in prostate cancer.

Su S, Wang Y, Lo E, Tamukong P, Kim H Transl Oncol. 2025; 53:102293.

PMID: 39862483 PMC: 11803900. DOI: 10.1016/j.tranon.2025.102293.

Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.

Bitar R, Salem R, Finn R, Greten T, Goldberg S, Chapiro J Radiology. 2024; 313(2):e232875.

PMID: 39560477 PMC: 11605110. DOI: 10.1148/radiol.232875.

Integrating single-cell transcriptomics and machine learning to predict breast cancer prognosis: A study based on natural killer cell-related genes.

Mao J, Liu L, Shen Q, Cen M J Cell Mol Med. 2024; 28(15):e18549.

PMID: 39098994 PMC: 11298315. DOI: 10.1111/jcmm.18549.

Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.

Holtermann A, Gislon M, Angele M, Subklewe M, von Bergwelt-Baildon M, Lauber K BioDrugs. 2024; 38(5):611-637.

PMID: 39080180 PMC: 11358237. DOI: 10.1007/s40259-024-00669-y.

Manipulating the Crosstalk between Cancer and Immunosuppressive Cells with Phototherapeutic Gold-Nanohut for Reprogramming Tumor Microenvironment.

Cheng H, Lee W, Hsu F, Lai Y, Huang S, Lim C Adv Sci (Weinh). 2024; 11(32):e2404347.

PMID: 38923327 PMC: 11348132. DOI: 10.1002/advs.202404347.

References

Spranger S, Dai D, Horton B, Gajewski T . Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4. PMC: 5650691. DOI: 10.1016/j.ccell.2017.04.003. View

Takahashi T, KUNIYASU Y, Toda M, Sakaguchi N, Itoh M, Iwata M . Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1999; 10(12):1969-80. DOI: 10.1093/intimm/10.12.1969. View

Tselikas L, Champiat S, Sheth R, Yevich S, Ammari S, Deschamps F . Interventional Radiology for Local Immunotherapy in Oncology. Clin Cancer Res. 2021; 27(10):2698-2705. DOI: 10.1158/1078-0432.CCR-19-4073. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Gros A, Parkhurst M, Tran E, Pasetto A, Robbins P, Ilyas S . Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016; 22(4):433-8. PMC: 7446107. DOI: 10.1038/nm.4051. View

Fend L, Yamazaki T, Remy C, Fahrner C, Gantzer M, Nourtier V . Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Res. 2017; 77(15):4146-4157. DOI: 10.1158/0008-5472.CAN-16-2165. View

Den Brok M, Sutmuller R, van der Voort R, Bennink E, Figdor C, Ruers T . In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004; 64(11):4024-9. DOI: 10.1158/0008-5472.CAN-03-3949. View

Bottero V, Withoff S, Verma I . NF-kappaB and the regulation of hematopoiesis. Cell Death Differ. 2006; 13(5):785-97. DOI: 10.1038/sj.cdd.4401888. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

10.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

11.

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

12.

Shao Q, OFlanagan S, Lam T, Roy P, Pelaez F, Burbach B . Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int J Hyperthermia. 2019; 36(1):130-138. DOI: 10.1080/02656736.2018.1539253. View

13.

Hegde P, Karanikas V, Evers S . The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res. 2016; 22(8):1865-74. DOI: 10.1158/1078-0432.CCR-15-1507. View

14.

Walker L, Sansom D . The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11(12):852-63. DOI: 10.1038/nri3108. View

15.

Khokhlova V, Fowlkes J, Roberts W, Schade G, Xu Z, Khokhlova T . Histotripsy methods in mechanical disintegration of tissue: towards clinical applications. Int J Hyperthermia. 2015; 31(2):145-62. PMC: 4448968. DOI: 10.3109/02656736.2015.1007538. View

16.

Linsley P, Greene J, Brady W, Bajorath J, Ledbetter J, Peach R . Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994; 1(9):793-801. DOI: 10.1016/s1074-7613(94)80021-9. View

17.

van Hooren L, Sandin L, Moskalev I, Ellmark P, Dimberg A, Black P . Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol. 2016; 47(2):385-393. DOI: 10.1002/eji.201646583. View

18.

Tavare R, Escuin-Ordinas H, Mok S, McCracken M, Zettlitz K, Salazar F . An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res. 2015; 76(1):73-82. PMC: 4703530. DOI: 10.1158/0008-5472.CAN-15-1707. View

19.

Katz S, Hardaway J, Prince E, Guha P, Cunetta M, Moody A . HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA liver metastases. Cancer Gene Ther. 2019; 27(5):341-355. DOI: 10.1038/s41417-019-0104-z. View

20.

Blackburn S, Shin H, Freeman G, Wherry E . Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci U S A. 2008; 105(39):15016-21. PMC: 2567485. DOI: 10.1073/pnas.0801497105. View